Listed below are a very powerful news items that investors need to start out their trading day:
1. Dow on a tear
2. Bank earnings drive the day
3. Goldman drops recession odds
4. Musk and Zuck will spar … with Congress
No matter whether or not they square off in a cage match, Elon Musk and Mark Zuckerberg have fights ahead. Democrats and Republicans in Congress are dialing up their scrutiny of the tech moguls and their businesses as each men expand their empires. On the Senate side, Sen. Elizabeth Warren, D-Mass., asked the Securities and Exchange Commission to probe Tesla over its CEO Musk’s takeover of Twitter. She cited potential conflicts of interest, just like the prospect of using the social media platform to profit Tesla, and “misappropriation of corporate assets.” Meanwhile, the Republican-led House Judiciary Committee prolonged its probe of content moderation on the Zuckerberg-led Meta‘s social platforms to its latest Twitter competitor Threads. GOP lawmakers have long raised concerns about what they call efforts to curb conservative speech on social platforms.
5. Alzheimer’s and RSV breakthroughs
Thousands and thousands of Alzheimer’s patients could soon have more treatment options than seemed possible only a number of months ago. Eli Lilly said it applied for FDA approval of its promising Alzheimer’s treatment donanemab, which slowed the disease in patients treated within the early stages of its progression as a part of a phase three trial. The corporate expects a call from the agency by the top of the 12 months. It follows the approval of Eisai and Biogen‘s treatment Leqembi, which opened the door for broader Medicare coverage of the similarly promising treatment. Alzheimer’s is notoriously hard to treat, and the potential approval of two drugs to combat the disease may very well be a game changer for patients across the U.S. However the treatments could prove expensive and hard to return by for months or years, and each bring the danger of negative effects like brain swelling or bleeding. The FDA also signed off on the primary shot that protects all infants from respiratory syncytial virus no matter whether or not they are healthy or have a medical condition.
– CNBC’s Samantha Subin, Hugh Son, Lauren Feiner, Lora Kolodny, Annika Kim Constantino, Spencer Kimball, Lee Ying Shan and Jeff Cox contributed to this report.
— Follow broader market motion like a professional on CNBC Pro.
